Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patientsSARS-CoV-2 및 COVID-19 환자의 우려 변종에 대한 면역 회피 및 중화 항체 역가의 시간적 감소Article Published on 2022-05-012022-09-11 Journal: Clinical immunology (Orlando, Fla.) [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acquisition Alpha Beta Breakthrough infection breakthrough infections Chronological change concerning Course COVID-19 COVID-19 patient COVID-19 patients D614G decrease Delta delta variant disease severity ELISA enrolled examined Gamma Immune evasions Infection Neutralizing antibodies neutralizing antibody Neutralizing titer neutralizing titers prevalent strain problem SARS-CoV-2 strain Strains thought titers vaccination variant variants of concern variants of SARS-CoV-2 Variants strain. Wuhan Wuhan-Hu-1 [DOI] 10.1016/j.clim.2022.108999 PMC 바로가기 [Article Type] Article
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice변이체 일치 또는 과거 mRNA 백신으로 부스팅하면 마우스에서 오미크론 감염으로부터 보호Article Published on 2022-04-282022-09-11 Journal: Cell [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody Antibody titers booster Breakthrough infection cytokine Cytokines dose Efficacy ENhance evaluated Immunity Infection Inflammation inflammation in the lungs inhibited less Lineage lung Lungs mice Moderna mRNA-1273 vaccine mRNA mRNA vaccine mRNA-1273 mRNA-1273 vaccine neutralization neutralized Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers Neutralizing titer neutralizing titers omicron Pathogenesis pathogenesis. PROTECT Protective SARS-CoV-2 SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 variants Strains Substitution vaccination Vaccine variant Viral viral burden WA1/2020 [DOI] 10.1016/j.cell.2022.03.037 PMC 바로가기 [Article Type] Article
Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals경증-증상이 있는 개인의 SARS-CoV-2에 대한 체액 반응의 바이러스학적 및 임상적 결정인자Article Published on 2022-04-282022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] acute infection age anti-SARS-CoV-2 antibody Antibody titer clinical cohort study contribute COVID-19 determinant duration of symptom ELISA female group healthy individual humoral Humoral response humoral responses individual magnitude median Mild mild COVID-19 patients Negative PCR Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody neutralizing response Neutralizing titer Older age plasma positive PCR pseudovirus recruited response RT-qPCR SARS-CoV-2 SARS-CoV-2-infected individuals Seroconversion symptom duration Symptoms viral dynamics Viral load Viral load. [DOI] 10.3389/fimmu.2022.860215 PMC 바로가기 [Article Type] Article
Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection Research Published on 2022-04-272022-10-05 Journal: Nature Communications [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료법, [키워드] administration Alpha anti-SARS-CoV-2 Clinical management clinical study convalescent COVID-19 distribution Endpoint EudraCT evaluated in vitro intramuscular Intramuscular injection mAb monoclonal antibody neutralize Neutralizing titer Omicron variant pharmacokinetic primary endpoint Prophylaxis reduced resulting Safe Safety SARS-CoV-2 variant SARS-CoV-2 variants secondary sera serum Serum Neutralization severe adverse events significantly single dose subjects therapy [DOI] 10.1038/s41467-022-29909-x [Article Type] Research
Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients간략한 연구 보고서: 입원 시 바이러스 특이적 체액 면역은 예방 접종을 받지 않은 SARS-CoV-2 환자의 호흡 부전 발병을 예측합니다Article Published on 2022-04-252022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] Admission adult COVID-19 patient analyzed Antibody titer association carried Characteristics Clinical management Cohort COVID COVID disease severity COVID-19 cross-sectional development disease disease severity ELISA Evidence failure group hospital Hospital admission humoral humoral immune response humoral response. IgG IgG1 IgG3 IgM IgM 2 Infection lowest Neutralization assay Neutralizing neutralizing antibody Neutralizing antibody titer Neutralizing titer non-survivor Oxygen therapy participant Patient patients positive correlation Prognostic marker receiving required respiratory Respiratory failure response variable robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 patients serum sample severe disease significantly higher significantly lower survived Survivors the patient variable [DOI] 10.3389/fimmu.2022.878812 PMC 바로가기 [Article Type] Article
Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2)가 장기간 지속되면 회복된 COVID-19 환자에서 단백질 특이성 및 중화 항체가 급증합니다.Article Published on 2022-04-212022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-RBD anti-receptor-binding domain Anti-spike Antibody Response Antibody responses Antibody titers Asymptomatic individuals blood sample Blood samples Cohort cohort of patient collected confirmed case coronavirus coronavirus disease Coronavirus disease 2019 correlation COVID-19 disease enrolled half-life IgA IgG IgG antibody IgG antibody titer Immunoglobulin immunological individual Infection Mild Mild disease Neutralizing neutralizing antibody Neutralizing titer neutralizing titers participant persistence Protein RBD recovered COVID-19 patient Recovered COVID-19 patients remained respiratory RT-PCR SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein Seropositivity serum antibody severe disease significantly Support symptom onset symptom severity total Ig understanding Vaccine wild-type SARS-CoV-2 [DOI] 10.1371/journal.pone.0267102 PMC 바로가기 [Article Type] Article
Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers의료 종사자의 COVID-19 예방 접종 6개월 후 항체 반응의 지속성 및 SARS-CoV-2 감염 빈도Article Published on 2022-04-012022-09-11 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody BNT162b2 breakthrough infections coronavirus coronavirus disease COVID-19 decay defined Delta Evidence evidence of exhibiting healthcare healthcare worker Healthcare workers Month Neutralizing titer neutralizing titers nucleocapsid protein postvaccination respiratory respiratory infections response SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 symptomatic tested United States vaccine-preventable diseases viruses wild-type virus worker zoonoses zoonoses. [DOI] 10.3201/eid2804.212037 PMC 바로가기 [Article Type] Article
Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose두 번째 백신 접종 후 180일 동안 의료 종사자(HW)에서 BNT162b 백신 2회 접종 후 세포 및 체액 면역 반응 및 돌발 감염Article Published on 2022-03-312022-09-12 Journal: Frontiers in Public Health [Category] MERS, SARS, 진단, [키워드] age all subject binding antibody BNT162b Breakthrough infection Cytopathic effect Day Delta VOC Dilution domain enrolled evaluated groups healthcare Healthcare workers highest Hospitalization human serum humoral Humoral response identify IFN-γ IgG IgG level IgG levels IgG titer Immunity individuals Infection information Live virus long-lasting maintain microneutralization mRNA vaccine mRNA vaccines mRNA vaccines. neutralized neutralizing antibody Neutralizing antibody titer neutralizing responses Neutralizing titer Older Predictive protective immunity Protein remained response SARS-CoV-2 second secretion shown stages subject subjects T-cell Response tested threshold Vaccine virus Volume was determined worker Wuhan strain [DOI] 10.3389/fpubh.2022.847384 PMC 바로가기 [Article Type] Article
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies Research Published on 2022-03-232022-10-05 Journal: Nature Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome administration analyzed antibody antibody treatment coronavirus country delta variant elevated immunocompromised individual individual individuals Infection inhibited mAbs monoclonal antibody Mutation neutralization neutralized Neutralizing activity Neutralizing titer nine not neutralize noticeable difference omicron Patient Prevent receiving recipient recipients reduced SARS-CoV-2 sensitivity sera therapeutic treated [DOI] 10.1038/s41591-022-01792-5 [Article Type] Research
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansSARS-CoV-2 단일클론항체 조합인 AZD7442는 인간이 아닌 영장류를 보호하고 인간에서 반감기가 연장됩니다.Article Published on 2022-03-092022-09-11 Journal: Science Translational Medicine [Category] MERS, SARS, 변종, 비임상, 진단, 치료기술, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration angiotensin angiotensin-converting enzyme 2 Angiotensin-converting enzyme 2 receptor antibody benefit binding cell entry cilgavimab Combination Concentration convalescent serum coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 death Epitopes extrapolation fold functions geometric geometric mean greater half-live healthy Human individual Infection Initially Intramuscular injection lung mAb mAbs monoclonal antibodies monoclonal antibody combination nasal mucosa neutralize Neutralizing titer nonoverlapping epitope nonoverlapping epitopes participant Phase 1 phase 1 study Prevent prevented Prophylactic Protective provided receptor Receptor binding domain reduce remained respiratory risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant serum severe acute respiratory syndrome Coronavirus severe disease Spike protein Spike protein receptor binding domain tested the spike protein therapeutic Tixagevimab treat Treatment Vaccines Viral viral spike protein virus virus clearance [DOI] 10.1126/scitranslmed.abl8124 PMC 바로가기 [Article Type] Article